Ask AI
ProCE Banner Activity

Applying HER2 Testing Results to Treatment Decisions for Patients With NSCLC

Slideset

Download this slideset for expert perspectives and key data on HER2-targeted therapy for specific patients with advanced lung cancer. 

Released: March 24, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

 
ProCE Banner

Supporters

Supported by educational grants from Boehringer Ingelheim Pharmaceuticals, Inc. and Jazz Pharmaceuticals, Inc.

Boehringer Ingelheim Pharmaceuticals, Inc.

Jazz Pharmaceuticals, Inc.

Target Audience

This educational activity is intended for pathologists, oncologists, and other laboratory and healthcare professionals involved in the precision care of patients with HER2-altered solid tumors.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Implement pathological procedures to identify patients with solid tumors who may benefit from HER2-targeted therapy consistent with the latest guidelines and expert recommendations

  • Assess the clinical implications of accurate HER2 evaluation for patients with solid tumors based on the latest clinical trial evidence and FDA approvals

  • Apply evidence-based approaches to standardize HER2 scoring and reporting in clinical practice

  • Collaborate with the multidisciplinary team to optimize treatment strategies for patients with HER2-altered solid tumors

Disclosure

Primary Author

Jonathan E. Dowell, MD: consultant/advisor/speaker: Genentech, Nuvation, Pfizer.